Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268429 | 0.94 | DHFR (0.50) | DHFRNTRK1LMNA | |
| SCHEMBL3271309 | 0.93 | DHFR (0.53) | DHFREGFRMEN1KMT2ACYP1A2 | |
| SCHEMBL3267162 | 0.89 | NTRK1 (0.52) | DHFRNTRK1 | |
| SCHEMBL3267190 | 0.89 | DHFR (0.50) | DHFREGFRMEN1KMT2A | |
| SCHEMBL3268137 | 0.83 | CYP1A2 (0.47) | DHFRMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3268743 | 0.82 | NTRK1 (0.48) | DHFRNTRK1MEN1KMT2ACYP1A2 | |
| SCHEMBL3273799 | 0.79 | KCNH2 (0.46) | DHFRNTRK1MEN1KMT2ACYP1A2 | |
| SCHEMBL3267284 | 0.79 | EGFR (0.48) | DHFREGFRMEN1KMT2ACYP1A2 | |
| SCHEMBL8509984 | 0.77 | KCNH2 (0.49) | NTRK1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3267065 | 0.75 | MEN1 (0.53) | EGFRMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| EP-2195296-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040290-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088451-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | DHFR 499/4885NTRK1 529/4885EGFR 2531/4885 |
| US-20120136018-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | DHFR 499/4885NTRK1 529/4885EGFR 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.